Novalgen_logo_on_white.jpg
NovalGen announces one oral and two poster presentations at the American Society of Hematology Annual Meeting
03 nov. 2022 09h58 HE | NovalGen Ltd.
-Updated clinical data for NVG-111, a novel ROR1xCD3 bispecific antibody in patients with relapsed / refractory CLL and MCL -- Pre-clinical data for a first in class half-life extended T Cell engager...